Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Zofia Piotrowska, MD, MHS
Massachusetts General Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Maryland Oncology Hematology
Calverton, Maryland, United States
Recruiting - Massachusetts General Hospital
Boston, Massachusetts, United States
Not, yet, recruiting - Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
Recruiting - Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Recruiting - Next Houston
Houston, Texas, United States
Recruiting - Next Virginia
Fairfax, Virginia, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Dec 2025
- Primary completion
- 31 Dec 2026
- Completion
- 30 Jun 2027
- Last update posted
- 9 Jul 2026
- Registered enrollment
- 18
- Registry id
- NCT07315113
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.